Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 18, 2024Leukemia & lymphoma/Leukemia and lymphomaOpen Access

An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study

View Full Paper
Ask AI
Bookmark
Share

Authors

APAurore PerrotSDSosana DelimpasiESEmmanouil Spanoudakis

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Perrot et al. (2024) studied this question.

synapsesocial.com/papers/68e7376bb6db6435876b1039https://doi.org/10.1080/10428194.2024.2322030
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world efficacy and safety of the carfilzomib–pomalidomide–dexamethasone regimen in patients with relapsed/refractory multiple myeloma: A multicenter retrospective study2026
  2. 2Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study2024 · 5 citations
  3. 3A real-world study on first-line early switch to kpd regimen in the treatment of multiple myeloma patients with suboptimal induction efficacy or intolerance2025
  4. 4Aponermin combined with carfilzomid-pomalidomide-dexamethasone (KPd) in patients with relapsed or refractory multiple myeloma: A prospective, open-label, multicenter study2025
  5. 5Final analysis of daratumumab, carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.2026